Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation

In Vivo

Volumn 13, Issue 3, 1999, Pages 199-204

  Hokland, Marianne ^a   KjÆrgaard, Jørgen ^a   Kuppen, Peter J K ^b   Nannmark, Ulf ^a   Agger, Ralf ^a   Hokland, Peter ^a   Basse, Per ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

A NK cells; B16 melanoma; Interleukin 2; Pulmonary metastases; T LAK cells

Indexed keywords

CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 2; MITOGENIC AGENT;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; IMMUNOSTIMULATION; INOCULATION; LUNG METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION;

EID: 0032794633     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Mazumder A, Rosenberg SA: Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 159: 495-507, 1984.
2. Mult JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487-1489, 1984.
3. Okada K, Nannmark U, Vujanovic NL, Watkins S, Basse P, Herberman RB & Whiteside TL: Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer. Cancer Res 56: 1599-1608, 1996.
4. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH: Accumulation of adoptively transferred adherent lymphokine-activated killer cells in murine metastases. J Exp Med 174: 479-488, 1991.
5. Kjφprgaard J, Hokland M, Nannmark U, Hokland P, Basse P: Infiltration patterns of short- and long-term cultured A-NK and T-LAK cells following adoptive immunotherapy. Scand J Immunol 47: 532-540, 1998.
6. Basse P, Goldfarb Rh, Herberman RB, Hokland M: Accumulation of adoptively transferred A-NK cells in murine metastases: Kinetics and role of IL-2. In Vivo 8: 17-24, 1994.
7. Gunji Y, Vujanivic NK, Hiserodt JC, Herberman RB, Gorelik E: Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J Immunol 142: 1748-1757, 1989.
8. Basse P, Hokland P, Gundersen HJ, Hokland M: Enumeration of organ-associated natural killer cells in mice: application of a new stereological method. APMIS 100: 202-208, 1992.
9. van den Brink MRM, Palomba ML, Basse PH, Hiserodt JC: In situ localization of 3.2.3+ natural killer cells in tissues from normal and tumor-bearing rats. Cancer Res 51: 4931-4936, 1991.
10. Talmadge JE, Phillips H, Schindler J, Tribble H, Pennington R: Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res 47: 5725-5732, 1987.
11. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161: 1169-1188, 1987.
12. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH: Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 174: 479-488, 1991.
13. Kuppen P, Basse PH, Goldfarb RH, Van der Velde CJH, Fleuren GJ, Eggermont AMM: The infiltration of experimentally induced lung metastases of colon carcinoma CC531 by adoptively transferred interleukin-2 activated natural killer cells in Wag rats. Int J Cancer 56: 574-579, 1993.
14. Matsumura T, Sussman JJ, Krinock RA, Chang AE, Shu S: Characteristic and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes. Cancer Res 54: 2744-2750, 1994.
15. Wallace PK, Palmer LD, Perry-Lalley D, Bolton ES, Alexander RB, Horan PK, Yang JC, Muirhead KA: Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells. Cancer Res 53: 2358-2387, 1993.
16. Butcher EC, Weissman EL: Direct fluorescent labeling of cells with fluorescein or rhodamine isothiocyanate. I. Technical aspects. J Immunol Methods 37: 97-102, 1980.
17. Butcher EC, Weissman EL: Direct fluorescent labeling of cells with fluorescein or rhodamine isothiocyanate. II. Potential application to studies of lymphocyte migration and maturation. J Immunol Methods 37: 109-116, 1980.
18. Makgoba MW, Sanders ME, Luce GEG, Gugel EA, Dustin ML, Springer TA, Shaw S: Functional evidence that intracellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol 18: 637-640, 1988.
19. Dustin ML, Carpen O, Springer TA: Regulation of locomotion and cell-cell contact area by the LFA-1 and ICAM-1 adhesion receptors. J Immunol 148: 2654-2663, 1992.
20. Mäenpää A, Jääskeläinen J, Carpen O, Patarroyo M, Timonen T: Expression of integrins and other adhesion molecules on NK cells: Impact of IL-2 on short- and long-term cultures. Int J Cancer 53: 850-855, 1993
21. Carlos TM, Harlan JM: Leukocyte-endothelial adhesion molecules. Blood 84: 068-2101, 1994.
22. Melder RJ, Walker ER, Herberman RB, Whiteside TL: Adhesion characteristic of human interleukin-2-activated natural killer cells. Cell Immunol 132: 177-192, 1991.
23. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK: During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 2: 992-997, 1996.
24. Cesario TC, Vaziri ND, Ulich TR, Khamiseh G, Oveisi F, Rahimzadeh M, Yousefi S, Pandian MR: Functional, biochemical, and histopathologic consequences of high-dose interleukin-2 administration in rats. J Lab Clin Med 118: 81-88, 1991.
25. Lotze MT, Matory YL, Ettinghausen SE, Rosenberg SA: In vivo administration of purified human interleukin-2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 135: 2865-2875, 1985.
26. Donohue J, Lotze MT, Robb R: In vivo administration of purified Jurkat derived interleukin-2 in mice. Cancer Res 44: 1380-1386, 1984
27. Maghazachi A, Herberman RB, Vujanovic NL, Hiserodt JC: In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells. Cell Immunol 115: 179-194, 1988
28. Basse PH, Herberman RB, Hokland ME, Goldfarb RH: Tissue distribution of adoptively transferred adherent LAK cells: role of the route of administration. Nat Immun 11: 193-202, 1992